pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Biopharma 98

Biopharma Sales Manufacturing Pharma 98

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 110

Biopharma Sales Prescription FDA 110

European Pharmaceutical Review

APRIL 18, 2023

GSK has agreed to acquire late-stage biopharma BELLUS Health, for a total of £1.6 Camlipixant, a novel P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential,” Miels added. According to GSK, the P2X3 antagonist has the potential to deliver significant sales through 2031 and beyond.

Biopharma 98

Biopharma Sales Patients Medical 98

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52